Stocktoria
Nautilus Biotechnology, Inc. NAUT
Nautilus Biotechnology, Inc. (NAUT) earns a Piotroski F-score of 1/9 (weak financial health). It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NAUT | Nautilus Biotechnology, Inc. | 1/9 | — | — | — |
| A | AGILENT TECHNOLOGIES, INC. | 5/9 | 3.48 | 29.5 | +6.7% |
| AVTR | Avantor, Inc. | 4/9 | 1.86 | — | -3.4% |
| ILMN | ILLUMINA, INC. | 7/9 | 3.04 | 31.4 | -0.7% |
| MTD | METTLER TOLEDO INTERNATIONAL INC/ | 5/9 | — | 29.4 | +4% |
| BRKR | BRUKER CORP | 4/9 | 2.98 | — | +2.1% |
| WAT | WATERS CORP /DE/ | 4/9 | 10 | 55.1 | +7% |
About Nautilus Biotechnology, Inc.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
FAQ
Is NAUT financially healthy?
Nautilus Biotechnology, Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak).
Does NAUT pay a dividend?
No, Nautilus Biotechnology, Inc. does not currently pay a dividend.
How profitable is NAUT?
In FY2025, Nautilus Biotechnology, Inc. had a return on equity of -37.6%.
What is the analyst price target for NAUT?
The average Wall-Street price target for Nautilus Biotechnology, Inc. is $4.00, about 344.6% above the recent price, from 1 analysts.
Is NAUT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Nautilus Biotechnology, Inc.: a Piotroski F-score of 1/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.